

Genomic Dose Response: The Ficture

NTP Genomic Dose Response Modeling Expert Panel Meeting October 23, 2017

Russell Thomas Director National Center for Computational Toxicology

The views expressed in this presentation are those of the author and do not necessarily reflect the views or policies of the U.S. EPA



Scott May Want To Rethink Asking Me To Be The "Big Picture Guy"...





It is a Well Known Fact that Toxicology Continues to Have a Data Problem

Toxicity Testing

Strategies to Determine Needs and Priorities

Steering Committee on Identification of Toxic and Potentially Toxic Chemicals for Consideration by the National Toxicology Program

Board on Toxicology and Environmental Health Hazards

Commission on Life Sciences

National Research Council

- Major challenge is too many chemicals and not enough data
- Total # chemicals = 65,725
- Chemicals with no toxicity data of any kind = ~46,000

NATIONAL ACAD	EMY PRESS
Washington, D.C.	1984

US Nation	alRes	sea	arch	n C	ou	ncil	, 19	984
Category	Size of Category		Estimate Mean Percent In the Select Universe					
Pesticides and Inert Ingredients of Pesticides Formulations	3,350							
CosmeticIngredients	3,410		10	24	2	26		38
Drugs and Excipients Used in Drug Formulations	1,815		2 14	10	18		56	
U U			18	1	18 3	36		25
Food Additives	8,627		5 14	1	34			46
Chemicals in Commerce: At Least 1 Million Pounds/Year	12,860		11	11		78		
Chemicals in Commerce: Lessthan 1 Million Pounds/Year	13,911		12	12		76		
Chemicals in Commerce: Production Unknown or Inaccessible	21,752		12	12		70		
			10 8			82		
Complete Part Health Heal Hazard Haza Assessment Asse Possible Poss	th rd ssment	Minir Toxici Infor Availa	ity mation	Inf Av	kicity ormatio ailable	n Minimal)	Info	oxicity rmation lable



It is a Well Known Fact that Toxicology Continues to Have a Data Problem

The Toxicity Data Landscape for Environmental Chemicals

Richard Judson,¹ Ann Richard,¹ David J. Dix,¹ Keith Houck,¹ Matthew Martin,¹ Robert Kavlock,¹ Vicki Dellarco,² Tala Henry,² Todd Holderman,² Philip Sayre,² Shirlee Tan,⁴ Thomas Carpenter,⁵ and Edwin Smith⁶

¹National Center for Computational Toxicology, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, North Carolina, USA; ²Office of Pesticide Programs, Office of Provention, Pasticides, and Toxic Substances, U.S. Environmental Protection Agency, Arington, Virginia, USA; ²Office of Polymonth Prevention and Toxics and ⁴Office of Science Coordination and Policy, Office of Prevention, Pesticides, and Toxic Substances, U.S. Environmental Protection Agency, Washington, DC, USA; ³Office of Water, Office of Ground Water and Urniking Water, U.S. Environmental Protection Agency, Washington, DC, USA; ⁴Great Lakes National Program Office, U.S. Environmental Protection Agency, Washington, DC, USA;

OBJECTNE: Thesauskie of chemicals are in common and, but only a pertiss of them have undergoes applicant transloople evaluation, leading to the need is proteitism the manifest for targeted testing. To address this issue, the U.S. Environmental Protection Agency (EPA) and other organizations are developing chemical screening and proteinization programs. As part of these efforts, it is important to catalog, free widely dispersed sources, the transload proteination that are catalodies for the weldble. The main objective of this analysis is to define a list of environmental chemicals that are catalodies for the U.S. EPA screening and proteination process, and to catalog the available. These matchings information.

DATA SOURCES: We are developing ACT of (Aggregated Computational Toxicology Resource), which combines information for handrude of thousands of chemicals from > 200 public sources, including the U.S. EPA, National Institution of Health, Food and Drug Administration, corresponding agencies in Canada, Europe, and Japan, and academic sources.

DATA EXTRACTION: ACTOR contains chemical structure information: physical-chemical properties: for ritre away data: tabular for robe data: summary totacology calls (e.g., a statement that a chemical is considered to be a human carcinogen); and links to online toracology summaries. Here, we use data from ACTOR to assess the totacity data landscape for environmental chemicals.

DATA STMINESS: We show easily for a set of 9,912 environmental chemicals being considered for analysis as part of the U.S. EPA TorCast screening and prioritization program. These include highand medium-production-volume chemicals, posticide active and inert ingredients, and drinking water contaminatio.

CONCLISION: Approximately two-thirds of these chemicals have at least limited toricity summarks available. About one-quarter have been assessed in at least one highly carated toxicology evaluation database such as the U.S. EPA Toxicology Reference Database, U.S. EPA Integrated Rule Information System, and the National Toxicology Program.

KIT WORDS: ACT/oR, carcinogenicky, database, dovelopmental, huzarl, HPV, MPV, posticide, reproductive, intuktiv, Entriven Health Penjaer 117:685-695 (2009). doi:10.1289/chp.0800168 analable via http://dx.doi.org/10.1018/22.Deamber 2008]

The U.S. Environmental Protection Agency (EPA) has a significant interest in developing more efficient and informative toxicity determination approaches in part because of the large number of chemicals under its ion. Ultimately, it would be beneficial to characterize the toxicologic profiles of all chemicals in use in the United States. However, the size of this chemical universe lin excess of 75,000 chemicals, which is the estimated number in the Toxic Substances Control Act (TSCA 1976) inventory (U.S. EPA 2004b) makes this goal too difficult using current approaches to toxicity characterization that rely on extensive animal testing, cost millions of dollars, and can take 2-3 years per chemical. The International Life Sciences Institute/Health and Environmental Sciences Institute (ILSI/HESI) recently released several reports describing a more focused, tier-based approach for toxicity testing of agricultural chemicals, which would ultimately lead to the use of fewer animals (Barton et al. 2006; Carmichael et al. 2006). The National Research Council (NRC)

recently released a report titled Toxicity Testing in the 21st Century: A Vision and a Strategy that outlines a much more ambitious and long-term vision for developing novel in sitre approaches to chemical toaicity characterization and prediction (NRC 2007) that would largely eliminate animal testing. The NRC report addresses several concerns about the current trating methods, specifically, the desire a) to reduce the number of animals used in testing, b) to reduce the overall cost and time required to characterize each chemical, and c) to increase the level of mechanistic understanding of chemical toxicity. The U.S. EPA and the National Institutes of Health (NIH) are actively pursuing approaches to implement ideas outlined in the NRC report (Collins et al. 2008).

Regardless of the level of quality of taxicology data on environmental chemicals, many chemicals lack significant amounts of data. In the United States and Canada, an estimated 30,000 chemicals are in wide commercial use, based on U.S. EPA and Environment Canada dats (Muir and Howard 2006). The European Union's Registration, Evaluation, and Authorization of Chemicals (REACH) program has recently released its first set of registered substances, which contains > 140,000 entries (REACH 2008). The exact number of chemicals in use is, in a sense, unknowable because it depends on where one sets the threshold of use and because use changes over time. The major point is that the number is relatively large and that only a relatively small subset of these chemicals have been sufficiently well characterized for their potential to cause human or ecologic toxicity to support regulatory action. 'This "data gap" is well documented (Allanou et al. 1999; Applegate and Baer 2006; Bimbaum et al. 2003; Guth et al. 2005; NRC 2007: U.S. EPA 1998).


The high cost and lengthy times associated with the use of animal tening to determine a chemical's potential for tracity make this strategy imposedical for evaluating tene of thousands of chemicals, hence the large inventories of criating chemicals for which few or no test data are available. An alternative approach is to attempt to assues much larger numbers of chemicals by employing more discinct in time methods. One strategy applies a broad spectrum of relatively incepentive and rapid high-throughput screening

Address correspondence to R. Judson, U.S. Environmental Protection Agency, 109 T.W. Alexander Dr. (2020-101), Benesch Triangle Fair, NC 2771 1133, Teighnene (1919) 541-5005, Fair (1919) 541-104, E-multi judson richardigeng gor members of the U.S. EDA Agengated Computational Teathology Researce (ACTeR) development isam: T. Cashey, T. Tranne, and B. Spencer of Lockhead Martin, and F. Ellourni, D. Smith, J. Vadi, and K. Danid, We also acknowling the significant mathetion of M. Wolf (Lockhead Martin) in relation to the U.S. EPAA Dumbund Starture-Sourthub's Toatciny Das Network attacture inventiony incorporated into ACTed.

This article has been reviewed by the U.S. EPA and approved for publication. Approval does not signally that the contains accusatily reflect the views and policies of the agency, nor does mention of trade names or commencial products constitute endoncement or recommendation for use.

The authors declare they have no competing financial interests.

Received 8 September 2008; accepted 22 December 2008.



Modified from Judson et al., EHP 2009



For Those With Data, Have We Been **Truly Predictive or Just Protective?**

...data compiled from 150 compounds with 221 human toxicity events reported. The results showed the true positive human toxicity concordance rate of 71% for rodent and nonrodent species, with nonrodents alone being predictive for 63% of human toxicity and rodents alone for 43%.

Regulatory Toxicology and Pharmacology 32, 56-67 (2000) doi:10.1006/rtph.2000.1399, available online at http://www.idealibrary.com on Concordance of the Toxicity of Pharmaceuticals in Humans and in Animals Harry Olson,¹ Graham Betton,² Denise Robinson,³ Karluss Thomas,³ Alastair Monro,¹ Gerald Kolaja,⁴ Patrick Lilly,⁵ James Sanders,⁶ Glenn Sipes,⁷ William Bracken,⁸ Michael Dorato,⁹ Koen Van Deun,¹⁰ Peter Smith,¹¹ Bruce Berger,¹² and Allen Heller¹³ ¹Pfizer Inc., Groton, Connecticut; ²AstraZeneca Pharmaceuticals, Macclesfield, England; ³ILSI-HESI, Washington, DC, 20036; ⁴Pharmacia & UpJohn, Kalamazoo, Michigan; ⁵Boehringer Ingelheim Pharmaceuticals, Ridgefield, Connecticut; ⁶Rhone-Poulenc Rorer, Collegeville, Pennsylvania; ⁷University of Arizona, Tucson, Arizona; ⁸Abbott Laboratories, Abbott Park, Illinois; ⁹Eli Lilly and Co., Greenfield, Indiana; ¹⁰ Janssen Research Foundation, Beerse, Belgium; ¹¹ Monsanto-Searle Laboratories, Skokie, Illinois; ¹² Sanofi-Synthelabo, Inc., Malvern, Pennsylvania; and ¹³Bayer Corporation, West Haven, Connecticut

Received January 22, 2000

Table 2-2. Uncertainty/safety factors for various reference values						
		UF ^a				
Reference value	U _A	U _H	UL	UD	FQPA ^b	
ARE	1, 3, 10	1, 3, 10	1, 3, 10	ND	NA	
AEGL	1, 3, 10	1, 3, 10	3°	ND ^d	NA	
OPP acute and intermediate RfDs	10	10	3, 10	ND ^e	10 <u>+</u>	
OW HAs	1, 3, 10	1, 3, 10	1, 3, 10	case-specific	NA	
ATSDR MRLs	1, 3, 10	1, 3, 10	1, 3, 10	ND ^d	NA	

^a Uncertainty factors: U_A = animal-to-human; U_H = within-human variability;

Ur = LOAEL-to-NOAEL; Up = database deficiency.

^b Additional safety factor required under FQPA

^c Endpoint = lethality, not really a LOAEL-to-NOAEL adjustment in this case. ^d Database deficiencies considered, and a factor may be included for intermediate RfDs if, for

example, there is no reproduction and fertility study.

* Overlaps with the FQPA safety factor (see U.S. EPA, 2002b)

ND = not done NA = not applicable

December 2002 Final Report A REVIEW OF THE REFERENCE DOSE AND **REFERENCE CONCENTRATION PROCESSES** Prepared for the Risk Assessment Forum U.S. Environmental Protection Agency Washington, DC

National Center for Computational Toxicology EPA/630/P-02/002F




Budding Field of Toxicogenomics Promised to Change All That...





Initial Focus of Toxicogenomics Was on Inferring MOA





Focus Shifted Towards Supervised Classification Approaches

 related endpoints related endpoints Only a limited number of the context of the context	% accuracy for predicting cancer- tissues have been evaluated with adequate redundancy and to have a robust training set (Thomas <i>et</i> esponses in NTP database with ~50%	Prediction inogens in Aubrecht, w Kincaid, † icity Working ology and Safety e, Eli Lilly and Sandi-aventis al Institute of earch, Pood and 1869, *Abbot . Bristol-Myers San Francisco,
Discrimination for Genotoxic and Nongenotoxic Carcinogens by Expression Profiling in Primary Mouse Hepatocytes Improves	of General General General, inoscow 1555, 117009, Russia, and Sceneco, mc., of Joseph, inc	
Exposure Time Karen Mathijs,*† Karen J. J. Brauers,* Danyel G. J. Jennen,*† Andre Boorsma,*‡ Marcel H. M. van Her Ralph W. H. Gottschalk,* Jos C. S. Kleinjans,*† and Joost H. M. van Deff*+1 *Department of Health Risk Analysis and Taxicology. Faculty of Health, Medicine and Life Sciences, Massricht University, 6200 MD M Netherlands; †Netherlands Toxicogenomics Center, 6200 MD Maastricht, The Netherlands; and ‡TNO Quality of Life, 3700 AJ Zeist, Th Received June 12, 2009; accepted September 11, 2009	Prediction of carcinogenic potential by a toxicogenomic approach using rat hepatoma cells Kazunari Tsujimura, ¹² Makoto Asamoto, ¹³ Shugo Suzuki, ¹ Naomi Hokaiwado, ¹ Kumiko Ogawa ¹ and Tomoyuki Shirai ¹ ¹ ^o pepartment of Experimental Pathology and Tumor Biology, Nagoya City University, Graduate School of Medical Science, 1 Kawasumi, Mizuho-dho, Mizuho-ku Nagoya 467-8601, Japan; ² Chemical Svaluation and Research Institute, Hita Laboratory, Tokyo 1120004, Japan (Received April 4, 2006/Revised June 1, 2006/Accepted June 8, 2006/Online publication August 11, 2006)	




In Vivo Study to Assess Transcriptional and Apical Correlation

Chemical	Route	Doses ^c	Rodent Model	Time Point	Target Tissue
1,2,4-Tribromobenzene ^a	Gavage	<u>2.5, 5, 10</u> , 25, 75 mg/kg	Male Sprague Dawley rats	5 d, 2, 4, 13 wks	Eiver
Bromobenzene ^a	Gavage	25, (<u>50</u>), <u>100</u> , <u>200</u> , 300, <u>400</u> mg/kg	Male F344 rats	5 d, 2, 4, 13 wks	s Liver
2,3,4,6- Tetrachlorophenol ^a	Gavage	10, <u>25,</u> 50, <u>100,</u> <u>200</u> mg/kg	Male Sprague Dawley rats	5 d, 2, 4, 13 wks	Eiver
4,4'-Methylenebis (N,N- dimethyl) benzenamine ^b	Feed	50, 200, <u>375,</u> 500, <u>750</u> ppm	Male F344 rats	5 d, 2, 4, 13 wks	5 Thyroid ⁶
N-Njtrosodinhenvlamine ^b	Feed	250 1000 2000 3000 4000 ppm	Female E344 rate	5d 2 4 13 wks	Bladderb
Hyd Measured apica		gical and organ weight; n = each dose and time point		sion change	s (n = 5)
Propylene glycol mono-t- butyl ether ^ь	Inhalation	25, <u>75, 300,</u> 800, <u>1200</u> ppm	Female B6C3F1 mice	13 wks	Liver
1,2,3-Trichloropropane ^b	Gavage	2, <u>6, 20,</u> 40, <u>60</u> mg/kg	Female B6C3F1 mice	13 wks	Liver
Methylene Chloride ^b	Inhalation	100, 500, <u>2000,</u> 3000, <u>4000</u> ppm	Female B6C3F1 mice	13 wks	Liver, Lung
Naphthalene ^b	Inhalation	0.5, 3, <u>10</u> , 20, <u>30</u> ppm	Female B6C3F1 mice	13 wks	Lung
1,4-Dichlorobenzene ^b	Gavage	100, <u>300,</u> 400, 500, <u>600</u> mg/kg	Female B6C3F1 mice	13 wks	Liver

^aChemicals in IRIS database for non-cancer endpoints only ^bChemicals previously tested by the U.S. National Toxicology Program ^cUnderlined doses used in NTP two-year rodent bioassay or IRIS database




Temporal Changes Between Transcriptional and Non-Cancer PODs






Combined Correlation Between Non-Cancer and Transcriptional PODs






Temporal Changes Between Transcriptional and Cancer PODs



Thomas et al., Toxicol Sci, 2013



Combined Correlation Between Cancer and Transcriptional PODs




National Center for

Computational Toxicology



Why Could this Be True?

- Most histological changes do not occur without upstream or downsream changes in the transcriptome
- Most environmental chemicals are highly non-selective in their interactions with biological systems






Integration of TGX in a Tiered 21st Century Toxicity Testing Framework


TOXICOLOGICAL SCIENCES **136**(1), 4–18 2013 doi:10.1093/toxsci/kft178 Advance Access publication August 19, 2013


Incorporating New Technologies Into Toxicity Testing and Risk Assessment: Moving From 21st Century Vision to a Data-Driven Framework

Russell S. Thomas,^{*,1} Martin A. Philbert,[†] Scott S. Auerbach,[‡] Barbara A. Wetmore,^{*} Michael J. Devito,[‡] Ila Cote,[§] J. Craig Rowlands,[¶] Maurice P. Whelan,[∥] Sean M. Hays,^{|||} Melvin E. Andersen,^{*} M. E. (Bette) Meek,^{||||} Lawrence W. Reiter,[#] Jason C. Lambert,^{**} Harvey J. Clewell III,^{*} Martin L. Stephens,^{††} Q. Jay Zhao,^{**} Scott C. Wesselkamper,^{**} Lynn Flowers,[§] Edward W. Carney,[¶] Timothy P. Pastoor,^{‡‡} Dan D. Petersen,^{**} Carole L. Yauk,^{§§} and Andy Nong^{§§}












Developing a Portfolio of High-Throughput Toxicogenomic Tools



High-Throughput Transcriptomic Screen

- Low cost, 384-well, cell lysate compatible
- Whole transcriptome (EPA), S1500+ (NTP)
- Workflow integration of reference materials and controls, development of performance standards
- Portable platform/workflow for collaborative data generation

Mode of Action/MIE Analysis


- Refined CMAP tool and machine learning approaches
- Curating reference chemical database for MIE and directional response
- >60 MIEs and growing

Concentration Response Analysis

- BMDExpress 2.0
- Tcpl




Karmaus, Unpublished






Expanding the Tiered 21st Century Toxicity Testing Framework





International Case Study Evaluating Bioactivity as a Conservative POD






The Time is Now for Potential Regulatory Applications

I. R. 2576		
	One Hundred Fourteenth Congress	
	of the	
	United States of America	
	AT THE SECOND SESSION	
	Begun and held at the City of Washington on Monday, the fourth day of January, two thousand and sixteen	
	An Act	
	To modernize the Toxic Substances Control Act, and for other purposes.	
	Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,	


"(1) PRIORITIZATION FOR RISK EVALUATIONS.—

"(A) ESTABLISHMENT OF PROCESS.—Not later than 1 vear after the date of enactment of the Frank R. Lautenberg Chemical Safety for the 21st Century Act, the Administrator shall establish, by rule, a risk-based screening process, including criteria for designating chemical substances as high-priority substances for risk evaluations or low-priority substances for which risk evaluations are not warranted at the time. The process to designate the priority of chemical substances shall include a consideration of the hazard and exposure potential of a chemical substance or a category of chemical substances (including consideration of persistence and bioaccumulation, potentially exposed or susceptible subpopulations and storage near significant sources of drinking water), the conditions of use or significant changes in the conditions of use of the chemical substance, and the volume or significant changes in the volume of the chemical substance manufactured or processed.





But, A Necessary Piece Is Convergence and Acceptance of Analysis Approaches





Acknowledgements and Questions

Tox21 Colleagues: NTP FDA NCATS

EPA Colleagues: NERL NHEERL NCEA

Collaborative Partners: Unilever A*STAR ECHA EFSA Health Canada

